A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

SALT LAKE CITY - Lipocine Inc. (NASDAQ: NASDAQ:LPCN), a biopharmaceutical company with a market capitalization of approximately $24 million, announced today that it will conduct a phase 3 safety and ...

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...

Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those who had an inadequate response to oral antidepressants.

The small, Ireland-based company GH Research said its inhaled version of mebufotenin — a molecular cousin to psilocybin — was ...

Jan. 21 (UPI) --The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression. Johnson & Johnson's Spravato has been approved to treat a ...

AbbVie has reported new phase 3 data for its schizophrenia and bipolar disorder therapy Vraylar in treatment-resistant depression, as it waits for a decision by the FDA on the new indication.

Ketamine is a short-acting anesthetic that has been used for decades in medical settings. In recent years, researchers have ...

In a Phase IIb trial, GH001 elicited significant drops in treatment-resistant depression. The news comes less than two weeks ...

The inhaled mebufotenin candidate, dubbed GH001, was evaluated in the midstage study of 81 patients with treatment-resistant depression. The 40 patients who received GH001 saw an average 15.2 point ...

Major depression has one of the highest economic burdens of any psychiatric disorder,” he pointed out. Now, the FDA has also approved Spravato for treating adults with MDD who have not responded ...